OGI · Organigram Global Inc.

Organigram Global Inc. has received strong shareholder support for its strategic expansion into the European cannabis market through the acquisition of Sanity Group GmbH. The transaction received 93% approval from disinterested shareholders, demonstrating confidence in the deal's potential to enhance scale, revenue, and profitability. Sanity Group brings positive EBITDA from 2025 and provides Organigram with a vertically integrated European hub, including Europe's first two legal cannabis specialty stores in Switzerland. This acquisition positions Organigram to become a top player in Germany's medical cannabis market, the second largest federally legal market globally after Canada. The company also secured shareholder approval for all other meeting matters, including the election of ten directors with overwhelming support (each receiving over 98% votes for), reappointment of PricewaterhouseCoopers LLP as auditor with 97% approval, and authorization of unallocated equity awards under the company's incentive plan with 94% approval. The transaction remains subject to customary closing conditions including completion of the private placement financing with BAT and ATB Financial credit facilities, with closing anticipated in April 2026.